Cargando…

Cortactin expression predicts poor survival in laryngeal carcinoma

Amplification of the 11q13 region is one of the most frequent aberrations in squamous cell carcinomas of the head and neck region (HNSCC). Amplification of 11q13 has been shown to correlate with the presence of lymph node metastases and decreased survival. The 11q13.3 amplicon carries numerous genes...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibcus, J H, Mastik, M F, Menkema, L, de Bock, G H, Kluin, Ph M, Schuuring, Ed, van der Wal, J E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2266851/
https://www.ncbi.nlm.nih.gov/pubmed/18268491
http://dx.doi.org/10.1038/sj.bjc.6604246
_version_ 1782151571891552256
author Gibcus, J H
Mastik, M F
Menkema, L
de Bock, G H
Kluin, Ph M
Schuuring, Ed
van der Wal, J E
author_facet Gibcus, J H
Mastik, M F
Menkema, L
de Bock, G H
Kluin, Ph M
Schuuring, Ed
van der Wal, J E
author_sort Gibcus, J H
collection PubMed
description Amplification of the 11q13 region is one of the most frequent aberrations in squamous cell carcinomas of the head and neck region (HNSCC). Amplification of 11q13 has been shown to correlate with the presence of lymph node metastases and decreased survival. The 11q13.3 amplicon carries numerous genes including cyclin D1 and cortactin. Recently, we reported that FADD becomes overexpressed upon amplification and that FADD protein expression predicts for lymph node positivity and disease-specific mortality. However, the gene within the 11q13.3 amplicon responsible for this correlation is yet to be identified. In this paper, we compared, using immunohistochemical analysis for cyclin D1, FADD and cortactin in a series of 106 laryngeal carcinomas which gene correlates best with lymph node metastases and increased disease-specific mortality. Univariate Cox regression analysis revealed that high expression of cyclin D1 (P=0.016), FADD (P=0.003) and cortactin (P=0.0006) predict for increased risk to disease-specific mortality. Multivariate Cox analysis revealed that only high cortactin expression correlates with disease-specific mortality independent of cyclin D1 and/or FADD. Of genes located in the 11q13 amplicon, cortactin expression is the best predictor for shorter disease-specific survival in late stage laryngeal carcinomas.
format Text
id pubmed-2266851
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-22668512009-09-10 Cortactin expression predicts poor survival in laryngeal carcinoma Gibcus, J H Mastik, M F Menkema, L de Bock, G H Kluin, Ph M Schuuring, Ed van der Wal, J E Br J Cancer Molecular Diagnostics Amplification of the 11q13 region is one of the most frequent aberrations in squamous cell carcinomas of the head and neck region (HNSCC). Amplification of 11q13 has been shown to correlate with the presence of lymph node metastases and decreased survival. The 11q13.3 amplicon carries numerous genes including cyclin D1 and cortactin. Recently, we reported that FADD becomes overexpressed upon amplification and that FADD protein expression predicts for lymph node positivity and disease-specific mortality. However, the gene within the 11q13.3 amplicon responsible for this correlation is yet to be identified. In this paper, we compared, using immunohistochemical analysis for cyclin D1, FADD and cortactin in a series of 106 laryngeal carcinomas which gene correlates best with lymph node metastases and increased disease-specific mortality. Univariate Cox regression analysis revealed that high expression of cyclin D1 (P=0.016), FADD (P=0.003) and cortactin (P=0.0006) predict for increased risk to disease-specific mortality. Multivariate Cox analysis revealed that only high cortactin expression correlates with disease-specific mortality independent of cyclin D1 and/or FADD. Of genes located in the 11q13 amplicon, cortactin expression is the best predictor for shorter disease-specific survival in late stage laryngeal carcinomas. Nature Publishing Group 2008-03-11 2008-02-12 /pmc/articles/PMC2266851/ /pubmed/18268491 http://dx.doi.org/10.1038/sj.bjc.6604246 Text en Copyright © 2008 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Molecular Diagnostics
Gibcus, J H
Mastik, M F
Menkema, L
de Bock, G H
Kluin, Ph M
Schuuring, Ed
van der Wal, J E
Cortactin expression predicts poor survival in laryngeal carcinoma
title Cortactin expression predicts poor survival in laryngeal carcinoma
title_full Cortactin expression predicts poor survival in laryngeal carcinoma
title_fullStr Cortactin expression predicts poor survival in laryngeal carcinoma
title_full_unstemmed Cortactin expression predicts poor survival in laryngeal carcinoma
title_short Cortactin expression predicts poor survival in laryngeal carcinoma
title_sort cortactin expression predicts poor survival in laryngeal carcinoma
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2266851/
https://www.ncbi.nlm.nih.gov/pubmed/18268491
http://dx.doi.org/10.1038/sj.bjc.6604246
work_keys_str_mv AT gibcusjh cortactinexpressionpredictspoorsurvivalinlaryngealcarcinoma
AT mastikmf cortactinexpressionpredictspoorsurvivalinlaryngealcarcinoma
AT menkemal cortactinexpressionpredictspoorsurvivalinlaryngealcarcinoma
AT debockgh cortactinexpressionpredictspoorsurvivalinlaryngealcarcinoma
AT kluinphm cortactinexpressionpredictspoorsurvivalinlaryngealcarcinoma
AT schuuringed cortactinexpressionpredictspoorsurvivalinlaryngealcarcinoma
AT vanderwalje cortactinexpressionpredictspoorsurvivalinlaryngealcarcinoma